Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease
worldwide and the leading cause of liver-related morbidity and mortality. We aimed to …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …

Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …

Non-alcoholic fatty liver disease (NAFLD) is a challenging disease caused by multiple
factors, which may partly explain why it remains still orphan of an adequate therapeutic …

With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults …

Non-alcoholic fatty liver disease (NAFLD) is a challenging disease caused by multiple
factors, which may partly explain why it remains still orphan of an adequate therapeutic …

The number of individuals aged 65 or older is projected to increase globally from 524 million
in 2010 to nearly 1. 5 billion in 2050. Aged individuals are particularly at risk for developing …

Microphysiology systems (MPS), also called organs-on-chips and tissue chips, are
miniaturized functional units of organs constructed with multiple cell types under a variety of …